Engineering a bivalent anti-CsGRP78 nanobody via CDR grafting: in silico design and cytotoxic validation
Researchers have engineered a bivalent nanobody called CsGRP78-diaNb to target cancer cells that overexpress the GRP78 protein. Preliminary laboratory tests show the nanobody successfully induces cytotoxicity in cancer cells while sparing healthy cells.
Why it matters
This development offers a potential new therapeutic pathway for treating aggressive cancers by overcoming the limitations of traditional, full-length antibody treatments.
Scientific Reports ( 2026 ) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in